- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01543880
Safety and Efficacy of Long-term Somatropin Treatment in Adults (NordiWIN)
April 28, 2015 updated by: Novo Nordisk A/S
Non-interventional Study of Safety and Efficacy of Long-term Somatropin Treatment in Adults
This study is conducted in Europe.
The aim of the study is to evaluate safety and efficacy in adults treated with somatropin (Norditropin®).
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
752
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Mainz, Germany, 55127
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Adults in need of somatropin or current users
Description
Inclusion Criteria:
- In need of somatropin or current user
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Users of somatropin
|
Prescribed at the discretion of the treating physician according to product labelling
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of adverse events
Time Frame: Up to 10 years
|
Up to 10 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
BMI (Body Mass Index)
Time Frame: Up to 10 years
|
Up to 10 years
|
HbA1c change
Time Frame: Up to 10 years
|
Up to 10 years
|
IGF-I (Insulin-Like Growth Factor I)
Time Frame: Up to 10 years
|
Up to 10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2003
Primary Completion (ACTUAL)
December 1, 2013
Study Completion (ACTUAL)
June 1, 2014
Study Registration Dates
First Submitted
February 28, 2012
First Submitted That Met QC Criteria
February 28, 2012
First Posted (ESTIMATE)
March 5, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
April 29, 2015
Last Update Submitted That Met QC Criteria
April 28, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Other Study ID Numbers
- GH-1931
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Growth Hormone Disorder
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyFrance
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyDenmark
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in ChildrenIsrael, Denmark, Belgium, Spain, Macedonia, The Former Yugoslav Republic of, Turkey, United Kingdom, France, Slovenia, Czech Republic
-
Novo Nordisk A/SWithdrawnGrowth Hormone Disorder | Growth Hormone Deficiency in Children
-
Novo Nordisk A/SCompletedHealthy | Growth Hormone Disorder | Adult Growth Hormone DeficiencyUnited States
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in Children | Delivery SystemsGermany, Netherlands, Sweden
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyGermany
-
Novo Nordisk A/SCompletedHealthy | Growth Hormone DisorderDenmark
-
Novo Nordisk A/SCompletedHealthy | Growth Hormone DisorderGermany
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in Children | Growth Disorder | Idiopathic Short StatureUnited States
Clinical Trials on somatropin
-
Xiamen Amoytop Biotech Co., Ltd.Peking Union Medical College HospitalCompleted
-
PfizerActive, not recruitingPrader-Willi SyndromeJapan
-
GeneScience Pharmaceuticals Co., Ltd.The First Affiliated Hospital with Nanjing Medical University; Tongji Hospital and other collaboratorsActive, not recruiting
-
PfizerCompletedGrowth Hormone DeficiencyFrance
-
Novo Nordisk A/SCompletedNoonan Syndrome | Genetic DisorderSweden
-
Novo Nordisk A/SCompletedNoonan Syndrome | Genetic DisorderJapan
-
LG ChemCompletedBioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy VolunteersKorea, Republic of
-
Novo Nordisk A/SCompletedFoetal Growth Problem | Small for Gestational AgeJapan
-
Novo Nordisk A/SCompletedAchondroplasia | Genetic DisorderJapan
-
Novo Nordisk A/SCompletedNoonan Syndrome | Genetic DisorderSweden